Seroprevalence of viral hepatitis A, B, C, D and E viruses in the Hormozgan province southern Iran.

Autor: Behzadi MA; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Leyva-Grado VH; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Namayandeh M; Department of Clinical Virology, Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Namazi Hospital, Shiraz, Iran., Ziyaeyan A; Life Science student, Faculty of Arts and Science, University of Toronto, Toronto, Canada., Feyznezhad R; Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Dorzaban H; Hormozgan Health Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran., Jamalidoust M; Department of Clinical Virology, Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Namazi Hospital, Shiraz, Iran., Ziyaeyan M; Department of Clinical Virology, Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Namazi Hospital, Shiraz, Iran. ziyaeyanm@sums.ac.ir.
Jazyk: angličtina
Zdroj: BMC infectious diseases [BMC Infect Dis] 2019 Dec 03; Vol. 19 (1), pp. 1027. Date of Electronic Publication: 2019 Dec 03.
DOI: 10.1186/s12879-019-4661-4
Abstrakt: Background: Viral hepatitis is a global public health problem affecting millions of people worldwide, causing thousands of deaths due to acute and persistent infection, cirrhosis, and liver cancer. Providing updated serologic data can improve both surveillance and disease control programs. This study is aimed to determine the seroprevalence of markers for viral hepatitis (A, B, C, D and E) and the epidemiology of such infections in the general population of southern Iran's Hormozgan province.
Methods: Between 2016 and 2017, a total of 562 individuals with ages ranging from 1 to 86 years, who visited governmental public laboratories for routine check-ups, were tested for the presence of serological markers to hepatitis virus types A to E using enzyme-linked immunosorbent assays.
Results: The overall anti-hepatitis A virus (HAV) antibody seroprevalence was 93.2% (524/562). The prevalence of anti-hepatitis E virus (HEV) antibodies was 15.8% (89/562) among which 1.6% (9/562) of the seropositive individuals also had evidence of recent exposure to the virus (IgM positivity). Two and a half percent (14/562) were positive for hepatitis B surface (HBs) antigen, whereas 11.6% (65/562) tested positive for anti-hepatitis B core (HBc) antibodies. Among anti-HBc positive patients, 11% (7/65) had HBs Ag and 5% (3/65) were positive for anti-hepatitis D virus (HDV) antibodies. The prevalence of anti-hepatitis C virus (HCV) antibodies was 0.7% (4/562). The seroprevalence of anti-HAV, HEV IgG, anti-HBc antibodies, and HBs Ag increased with age.
Conclusion: The present study confirms a high seroprevalence of HAV infection among the examined population and reveals high levels of endemicity for HEV in the region. Planned vaccination policies against HAV should be considered in all parts of Iran. In addition, improvements on public sanitation and hygiene management of drinking water sources for the studied area are recommended.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje